A medicinal chemistry perspective for targeting histone H3 lysine-79 methyltransferase DOT1L.
about
Targeting histone methyltransferases and demethylases in clinical trials for cancer therapyChemical probes of histone lysine methyltransferasesDiscovery of Novel Dot1L Inhibitors through a Structure-Based Fragmentation ApproachRate of elongation by RNA polymerase II is associated with specific gene features and epigenetic modifications.Inhibition of histone H3K79 methylation selectively inhibits proliferation, self-renewal and metastatic potential of breast cancerSelective inhibitors of protein methyltransferasesOverexpression of SMYD2 contributes to malignant outcome in gastric cancer.Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyondThe histone methyltransferase DOT1L: regulatory functions and a cancer therapy target.DNA Methylation Targeting: The DNMT/HMT Crosstalk Challenge.Chromatin dynamics in kidney development and function.Inhibitors of emerging epigenetic targets for cancer therapy: a patent review (2010-2014).SAM/SAH Analogs as Versatile Tools for SAM-Dependent Methyltransferases.Targeting epigenetic regulators for cancer therapy: modulation of bromodomain proteins, methyltransferases, demethylases, and microRNAs.Inhibitors of Protein Methyltransferases and Demethylases.Optimization of a Fragment-Based Screening Hit toward Potent DOT1L Inhibitors Interacting in an Induced Binding Pocket.Nonclinical pharmacokinetics and metabolism of EPZ-5676, a novel DOT1L histone methyltransferase inhibitor.Disruptor of telomeric silencing 1-like (DOT1L): disclosing a new class of non-nucleoside inhibitors by means of ligand-based and structure-based approaches.Discovery of Potent, Selective, and Structurally Novel Dot1L Inhibitors by a Fragment Linking Approach.An efficient method for the synthesis of selenium modified nucleosides: its application in the synthesis of Se-adenosyl-L-selenomethionine (SeAM).
P2860
Q26746038-F01AFAF8-87C0-4EC3-AE76-D0B5B1B20699Q26829218-18E55E06-AC88-4458-9B33-9EB97B239EEFQ30392269-D3CCA3D0-6D88-4356-B233-CD6F5E5E54C4Q33657722-57B87726-ED94-47E8-A48C-F129F5EB2DA4Q34786534-1E766399-666F-4C3B-BCBA-6FF5BF53760CQ35135783-6DBA2BF2-FFB1-47D6-9C5E-AB595EA46CB3Q35677250-806D76E2-F434-4245-857B-A32850ABA5A8Q35967446-AC1B9DCA-ECF8-4133-96E2-00EAB4903C4EQ36250669-DFF9DA7F-737B-4D17-93A8-AFE1B379A47BQ37729405-B92D9C4E-8D5C-4CFD-818F-A8F7A968507AQ38210944-6E6C415A-D93B-4DB2-B923-512AAB23C17DQ38547122-46CE2BB3-CACA-4BF1-9E52-74B5879FF616Q38625953-FE279BEA-B8BB-4068-85CB-A9463F707D8BQ38707876-97150E9E-EC23-41B1-8F3D-5B8BD35A8EF1Q38740496-C4B2DBA6-81C8-449F-9CF3-5EFD06770682Q41826491-F8CBDC23-3BFB-4D34-802E-FB04939F259FQ46947333-BA3012AD-9DC7-436A-AC64-684A2BCB8AEAQ48238825-CDEEB396-B340-4D05-8FAB-B5ABB465CC3DQ48809898-C38A8B11-88EF-4F4F-BCF9-BE8028B1A398Q51820119-4306E5AB-67FB-4B54-9766-6C1727BE6C4C
P2860
A medicinal chemistry perspective for targeting histone H3 lysine-79 methyltransferase DOT1L.
description
2013 nî lūn-bûn
@nan
2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
A medicinal chemistry perspect ...... ne-79 methyltransferase DOT1L.
@ast
A medicinal chemistry perspect ...... ne-79 methyltransferase DOT1L.
@en
type
label
A medicinal chemistry perspect ...... ne-79 methyltransferase DOT1L.
@ast
A medicinal chemistry perspect ...... ne-79 methyltransferase DOT1L.
@en
prefLabel
A medicinal chemistry perspect ...... ne-79 methyltransferase DOT1L.
@ast
A medicinal chemistry perspect ...... ne-79 methyltransferase DOT1L.
@en
P2860
P356
P1476
A medicinal chemistry perspect ...... ne-79 methyltransferase DOT1L.
@en
P2093
Justin L Anglin
Yongcheng Song
P2860
P304
P356
10.1021/JM4007752
P407
P577
2013-08-14T00:00:00Z